Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a new contact lens sharpen both near and far vision for aging eyes?

NCT ID NCT05325931

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial tests whether a new daily disposable multifocal contact lens (kalifilcon A) can provide clear vision at both distance and near compared to an existing lens (samfilcon A) in people with presbyopia, the age-related loss of near vision. Adults aged 40 and older who already wear soft contact lenses will wear each type for about a week, and their visual sharpness will be measured. The study aims to see if the new lens offers a better option for managing presbyopia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
kalifilcon A daily disposable multifocal contact lenses
What this could lead to
If these lenses perform well, they could offer a more comfortable and convenient option for people with presbyopia who need help seeing both near and far.
What could go wrong
This is a small, short-term study, so results may not apply to everyone. Some people may find the lenses less comfortable or not as sharp as their usual ones.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Feb 2022

Finished

Mar 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be 40 years or older on the date the Informed Consent Form (ICF) is signed and have the capacity to read, understand and provide written voluntary informed consent. * Have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings. * Have no active ocular disease or allergic conjunctivitis. * Not be using any topical ocular medications. * Be willing and able to follow instructions. * Have signed a statement of informed consent. Exclusion Criteria: * Participating in a conflicting study. * Considered by the Investigator to not be a suitable candidate for participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Presbyopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bausch and Lomb

    Rochester, New York, 14609, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.